Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)

Abstract

Introduction: The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting. Methods: A multicenter retrospective non-comparative study was conducted on 224 people with T2DM on Oral anti-diabetics (OADs) or in combination with basal insulin who initiated treatment with iGlarLixi in Saudi Arabia. Data of at least 180 days (± 30 days) before and after initiating iGlarLixi were retrieved. Results: Mean HbA1c significantly decreased after iGlarLixi start, with a mean reduction of 1.6% at six months. The mean reduction in the FPG was −38.8 (95% CI -46.5 to −31.1, p < 0.001). The weight dropped from 86.17 kg to 83.33 kg after 6 months post-iGlarLixi initiation [mean reduction = −2.86, P < 0.001]. The incidence of reported hypoglycemia, symptomatic documented and/or severe cases, decreased from 0.513 (95% CI 0.33 to 0.76) per person-year at baseline to 0.002 (95% CI 0.001 to 0.011) six months after iGlarLixi. Conclusion: iGlarLixi is effective and well tolerated for improved glycemic control in patients with advanced therapy from OADs or insulin in Saudi Arabia.

Keywords

• Type-2 diabetes mellitus
• Insulin
• Glargine
• Lixisenatide
• iGlarLixi